Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
HeartBeam, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
Prev close 0.43 · gapped below the open, never looked back. High/low 0.43 at 3:45 pm ET, 0.40 at 11:15 am ET.
HeartBeam, Inc. has 9 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either HeartBeam, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On March 4, 2026, the Company announced ClearCardio as its first commercial customer.”
FILING10-K0001193125-26-104080cik 0001779372
“The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.”
FILING10-K0001193125-26-104080cik 0001779372
“The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.”
FILING10-K0001193125-26-104080cik 0001779372
“The study was a collaboration of Harvard Medical School Faculty at Beth Israel Deaconess Medical Center in Boston, MA, and Clinical Center of Serbia in Belgrade.”
FILING10-K0001193125-26-104080cik 0001779372
“The study was a collaboration of Harvard Medical School Faculty at Beth Israel Deaconess Medical Center in Boston, MA, and Clinical Center of Serbia in Belgrade.”
FILING10-K0001193125-26-104080cik 0001779372
“The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.”
FILING10-K0001193125-26-104080cik 0001779372
“The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.”
FILING10-K0001193125-26-104080cik 0001779372
“The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.”
FILING10-K0001193125-26-104080cik 0001779372
“The Company has an At-the-Market (ATM) sales agreement with Public Ventures, pursuant to which we may offer and sell from time to time, at our option, shares of the Company's common stock, $0.0001 par value per share (the "Shares").”
FILING10-K0001193125-26-104080cik 0001779372
“On March 10, 2026, the Company and the Icahn School of Medicine at Mount Sinai in New York ("Mount Sinai") entered into strategic AI collaboration to bring clinical-grade heart monitoring into the home.”
FILING10-K0001193125-26-104080cik 0001779372
Watchlist prices, news filtered to it, and its next report on your desk.
BEAT (HeartBeam, Inc.) has 9 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.